Overview

First-in-human Study of VE303 in Healthy Adult Volunteers

Status:
Completed
Trial end date:
2019-03-11
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate safety and tolerability of a range of doses of VE303 in healthy adult volunteers. The study also evaluated pharmacokinetics of intestinal colonization by the VE303 strains and pharmacodynamics of recovery of the gut microbiota after administration of antibiotics followed by a course of VE303.
Phase:
Phase 1
Details
Lead Sponsor:
Vedanta Biosciences, Inc.
Treatments:
Vancomycin